2021 World Virology and Bacteriology 90-County Market Assessment-100 Respiratory, STD, Enteric and Other Tests-Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers
This unique 90-country survey from LeadingMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.
The report is available by section, and can be customized to specific information needs and budget.
The report provides granular market segmentation analysis and forecasts for over 100 microbiology tests; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and strategies for suppliers.
Rationale
This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.
The infectious disease testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world’s major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.
Infectious Diseases Analyzed in the Report
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Carbapenemase, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, Norovirus, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Geographic Regions and Countries
Asia-Pacific
Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam
Europe
Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine
Latin America
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela
Middle East
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela
North America
Canada, Mexico, USA
Market Segmentation Analysis
Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
Opportunities and Strategies for Suppliers
The report is available by section, and can be customized to specific information needs and budget.
The report provides granular market segmentation analysis and forecasts for over 100 microbiology tests; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and strategies for suppliers.
Rationale
This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.
The infectious disease testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world’s major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.
Infectious Diseases Analyzed in the Report
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Carbapenemase, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, Norovirus, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Geographic Regions and Countries
Asia-Pacific
Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam
Europe
Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine
Latin America
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela
Middle East
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela
North America
Canada, Mexico, USA
Market Segmentation Analysis
- Sales and market shares of major suppliers of infectious disease diagnostic products in major countries by test.
- Test and sales forecasts for 100 infectious disease diagnostic assays by country, individual test and market segment:
- Review of market dynamics, trends, structure, size, growth and major suppliers.
- In-depth examination of major diseases, including their etiology, current diagnostic tests, vaccines, drugs and market needs.
- Review of major analyzers used for infectious disease testing, including their operating characteristics, features and selling prices.
- Assessment of emerging diagnostic technologies and their potential applications for infectious disease testing.
- Companies developing or marketing infectious disease diagnostic products by individual test.
Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
Opportunities and Strategies for Suppliers
- Emerging opportunities for new instrumentation, reagent systems, IT and other products with significant market appeal during the next five years.
- Design criteria for decentralized testing products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
I. INTRODUCTION
II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
IV. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. WORLDWIDE OVERVIEW OF MAJOR TESTS, TECHNOLOGIES AND INSTRUMENTATION
A. Major Infectious Disease Tests
1. AIDS: HIV/HIV-1/2/Combo, HIVAg/HIV NAT, Western Blot, HTLV-I/II
2. Adenovirus
3. Aeromonas
4. Anthrax/Bacillus Anthracis
5. Arboviruses
6. Babesiosis
7. Bacillary Epithelioid Angiomatosis (BEA) and Other Bartonella (Rochalimaea)
8. Blastocystis Hominis
9. Brucella
10. Campylobacter
11. Candida
12. Carbapenemase
13. Chagas Disease
14. Chancroid
15. Chlamydia
16. Clostridium Difficile
17. Coronaviruses
18. Coxsackieviruses
19. Creutzfeldt-Jakob’s Disease
20. Cryptosporidium Parvum
21. Cyclospora Cayetanensis
22. Cytomegalovirus
23. Ebola Virus
24. E. Coli
25. Echovirus
26. Encephalitis
27. Enteroviruses
28. Epstein-Barr Virus
30. Giardia Lamblia
31. Gonorrhea
32. Granuloma Inguinale
33. Hantavirus
34. Helicobacter Pylori
35. Hepatitis: HAV NAT, HBV NAT, HBs Ag, HCV, HCV NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, ALT/SGPT
36. Herpes Simplex Virus
37. Human Herpes Virus-6 (HHV-6)
38. Influenza Viruses
39. Legionella
40. Lyme Disease
41. Lymphogranuloma Venereum (LGV)
42. Malaria
43. Measles (Rubeola)
44. Meningitis
45. Microsporidium
46. Mononucleosis
47. Mumps
48. Mycoplasma
49. Norovirus
50. Papillomaviruses
51. Parvovirus B19
52. Pneumonia
53. Polyomaviruses
54. Pseudomonas Aeruginosa
55. Rabies
56. Respiratory Syncytial Virus (RSV)
57. Rhinoviruses
58. Rotavirus
59. Rubella
60. Salmonellosis
61. Septicemia
62. Shigellosis
VII. COUNTRY MARKET ANALYSES: INFECTIOUS DISEASE SCREENING TEST
Volume and Sales Forecasts for 90 Countries
Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Myanmar, Netherlands, New Zealand, Nicaragua, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam
VIII. COMPETITIVE ASSESSMENTS
Abbott
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Decode Genetics
Eiken Chemical
Elitech Group
Enzo Biochem
Exact Sciences
Fujirebio
Grifols
Hologic
Illumina
Leica Biosystems
Li-Cor Biosciences
Myriad Genetics
Ortho-Clinical Diagnostics
PerkinElmer
Proteome Sciences
Qiagen
Quest Diagnostics
Quidel
Roche
Scienion
Sequenom/LabCorp
Shimadzu
Siemens Healthineers
Sierra Molecular
Takara Bio
Tecan Group
Thermo Fisher
Wako Chemical
II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
IV. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. WORLDWIDE OVERVIEW OF MAJOR TESTS, TECHNOLOGIES AND INSTRUMENTATION
A. Major Infectious Disease Tests
1. AIDS: HIV/HIV-1/2/Combo, HIVAg/HIV NAT, Western Blot, HTLV-I/II
2. Adenovirus
3. Aeromonas
4. Anthrax/Bacillus Anthracis
5. Arboviruses
6. Babesiosis
7. Bacillary Epithelioid Angiomatosis (BEA) and Other Bartonella (Rochalimaea)
8. Blastocystis Hominis
9. Brucella
10. Campylobacter
11. Candida
12. Carbapenemase
13. Chagas Disease
14. Chancroid
15. Chlamydia
16. Clostridium Difficile
17. Coronaviruses
18. Coxsackieviruses
19. Creutzfeldt-Jakob’s Disease
20. Cryptosporidium Parvum
21. Cyclospora Cayetanensis
22. Cytomegalovirus
23. Ebola Virus
24. E. Coli
25. Echovirus
26. Encephalitis
27. Enteroviruses
28. Epstein-Barr Virus
30. Giardia Lamblia
31. Gonorrhea
32. Granuloma Inguinale
33. Hantavirus
34. Helicobacter Pylori
35. Hepatitis: HAV NAT, HBV NAT, HBs Ag, HCV, HCV NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, ALT/SGPT
36. Herpes Simplex Virus
37. Human Herpes Virus-6 (HHV-6)
38. Influenza Viruses
39. Legionella
40. Lyme Disease
41. Lymphogranuloma Venereum (LGV)
42. Malaria
43. Measles (Rubeola)
44. Meningitis
45. Microsporidium
46. Mononucleosis
47. Mumps
48. Mycoplasma
49. Norovirus
50. Papillomaviruses
51. Parvovirus B19
52. Pneumonia
53. Polyomaviruses
54. Pseudomonas Aeruginosa
55. Rabies
56. Respiratory Syncytial Virus (RSV)
57. Rhinoviruses
58. Rotavirus
59. Rubella
60. Salmonellosis
61. Septicemia
62. Shigellosis
VII. COUNTRY MARKET ANALYSES: INFECTIOUS DISEASE SCREENING TEST
Volume and Sales Forecasts for 90 Countries
Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Myanmar, Netherlands, New Zealand, Nicaragua, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam
VIII. COMPETITIVE ASSESSMENTS
Abbott
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Decode Genetics
Eiken Chemical
Elitech Group
Enzo Biochem
Exact Sciences
Fujirebio
Grifols
Hologic
Illumina
Leica Biosystems
Li-Cor Biosciences
Myriad Genetics
Ortho-Clinical Diagnostics
PerkinElmer
Proteome Sciences
Qiagen
Quest Diagnostics
Quidel
Roche
Scienion
Sequenom/LabCorp
Shimadzu
Siemens Healthineers
Sierra Molecular
Takara Bio
Tecan Group
Thermo Fisher
Wako Chemical
